AMOYTOP(SH:688278) Huan Qiu Wang·2026-01-12 09:46Core Viewpoint - The new basic medical insurance drug catalog and commercial insurance innovative drug catalog have been officially implemented as of January 1, 2026, significantly benefiting families of children with growth hormone deficiencies through the inclusion of the long-acting growth hormone Yipeisheng in the insurance coverage, which has seen a price reduction of over 50% [1] Group 1 - The long-acting growth hormone Yipeisheng, developed by Tebao Biopharmaceuticals, is now included in the medical insurance payment scope [1] - The price reduction of over 50% for Yipeisheng, combined with the medical insurance reimbursement policy, will greatly alleviate the financial burden on families of affected children [1] - Yipeisheng has completed the online listing process in all 31 provinces (regions, municipalities) across the country, with new policies being implemented to ensure timely access to the benefits for families [1]